Attached files

file filename
S-1 - FORM S-1 - Syndax Pharmaceuticals Incd39288ds1.htm
EX-3.4 - EX-3.4 - Syndax Pharmaceuticals Incd39288dex34.htm
EX-4.1 - EX-4.1 - Syndax Pharmaceuticals Incd39288dex41.htm
EX-3.1 - EX-3.1 - Syndax Pharmaceuticals Incd39288dex31.htm
EX-1.1 - EX-1.1 - Syndax Pharmaceuticals Incd39288dex11.htm
EX-3.2 - EX-3.2 - Syndax Pharmaceuticals Incd39288dex32.htm
EX-3.3 - EX-3.3 - Syndax Pharmaceuticals Incd39288dex33.htm
EX-4.2 - EX-4.2 - Syndax Pharmaceuticals Incd39288dex42.htm
EX-10.3 - EX-10.3 - Syndax Pharmaceuticals Incd39288dex103.htm
EX-10.5 - EX-10.5 - Syndax Pharmaceuticals Incd39288dex105.htm
EX-10.2 - EX-10.2 - Syndax Pharmaceuticals Incd39288dex102.htm
EX-10.6 - EX-10.6 - Syndax Pharmaceuticals Incd39288dex106.htm
EX-10.4 - EX-10.4 - Syndax Pharmaceuticals Incd39288dex104.htm
EX-10.8 - EX-10.8 - Syndax Pharmaceuticals Incd39288dex108.htm
EX-10.1 - EX-10.1 - Syndax Pharmaceuticals Incd39288dex101.htm
EX-10.7 - EX-10.7 - Syndax Pharmaceuticals Incd39288dex107.htm
EX-10.28 - EX-10.28 - Syndax Pharmaceuticals Incd39288dex1028.htm
EX-10.22 - EX-10.22 - Syndax Pharmaceuticals Incd39288dex1022.htm
EX-10.30 - EX-10.30 - Syndax Pharmaceuticals Incd39288dex1030.htm
EX-10.21 - EX-10.21 - Syndax Pharmaceuticals Incd39288dex1021.htm
EX-10.26 - EX-10.26 - Syndax Pharmaceuticals Incd39288dex1026.htm
EX-10.29 - EX-10.29 - Syndax Pharmaceuticals Incd39288dex1029.htm
EX-10.18 - EX-10.18 - Syndax Pharmaceuticals Incd39288dex1018.htm
EX-10.16 - EX-10.16 - Syndax Pharmaceuticals Incd39288dex1016.htm
EX-10.17 - EX-10.17 - Syndax Pharmaceuticals Incd39288dex1017.htm
EX-10.25 - EX-10.25 - Syndax Pharmaceuticals Incd39288dex1025.htm
EX-10.12 - EX-10.12 - Syndax Pharmaceuticals Incd39288dex1012.htm
EX-10.24 - EX-10.24 - Syndax Pharmaceuticals Incd39288dex1024.htm
EX-10.27 - EX-10.27 - Syndax Pharmaceuticals Incd39288dex1027.htm
EX-10.11 - EX-10.11 - Syndax Pharmaceuticals Incd39288dex1011.htm
EX-10.19 - EX-10.19 - Syndax Pharmaceuticals Incd39288dex1019.htm
EX-10.32 - EX-10.32 - Syndax Pharmaceuticals Incd39288dex1032.htm
EX-10.15 - EX-10.15 - Syndax Pharmaceuticals Incd39288dex1015.htm
EX-10.13 - EX-10.13 - Syndax Pharmaceuticals Incd39288dex1013.htm
EX-10.10 - EX-10.10 - Syndax Pharmaceuticals Incd39288dex1010.htm
EX-10.20 - EX-10.20 - Syndax Pharmaceuticals Incd39288dex1020.htm
EX-10.31 - EX-10.31 - Syndax Pharmaceuticals Incd39288dex1031.htm
EX-10.14 - EX-10.14 - Syndax Pharmaceuticals Incd39288dex1014.htm
EX-23.1 - EX-23.1 - Syndax Pharmaceuticals Incd39288dex231.htm
EX-21.1 - EX-21.1 - Syndax Pharmaceuticals Incd39288dex211.htm
EX-10.33 - EX-10.33 - Syndax Pharmaceuticals Incd39288dex1033.htm
EX-10.35 - EX-10.35 - Syndax Pharmaceuticals Incd39288dex1035.htm
EX-10.34 - EX-10.34 - Syndax Pharmaceuticals Incd39288dex1034.htm
EX-10.23 - EX-10.23 - Syndax Pharmaceuticals Incd39288dex1023.htm

Exhibit 10.9

AMENDMENT TO

SYNDAX PHARMACEUTICALS, INC.

2007 STOCK PLAN

WHEREAS, by written consent of the board of directors (the “Board”) of Syndax Pharmaceuticals, Inc. (the “Company”) adopted on August 18, 2015 and by written consent of the stockholders of the Company dated as of August 20, 2015, the Board and stockholders of the Company approved an amendment to the Company’s 2007 Stock Plan (the “Plan”) to amend the number of shares of the Company’s common stock that may be issued pursuant to awards granted under the Plan from 2,789,000 (which number of shares reserved under the Plan reflects a 1-for-12.3 reverse stock split of Common Stock effected by the Company on June 3, 2014) to 3,754,270.

The Plan is hereby amended in the following respects:

Effective as of August 20, 2015, Section 3 of the Plan is amended and restated in its entirely to read as follows:

“3. Stock Subject to the Plan. Subject to the provisions of Section 14 of the Plan, the maximum aggregate number of Shares that may be sold under the Plan is 3,754,270. The Shares may be authorized, but unissued, or reacquired Common Stock. If an award should expire or become unexercisable for any reason without having been exercised in full, or is surrendered pursuant to an Option Exchange Program, the unpurchased Shares that were subject thereto shall, unless the Plan shall have been terminated, become available for future grant under the Plan. In addition, any Shares of Common Stock which are retained by the Company upon exercise of an award in order to satisfy the exercise or purchase price for such award or any withholding taxes due with respect to such exercise or purchase shall be treated as not issued and shall continue to be available under the Plan. Shares issued under the Plan and later repurchased by the Company pursuant to any repurchase right which the Company may have shall be available for future grant under the Plan.”

[Signature Page Follows]


To record the adoption of this Amendment to the Plan, the Company has caused its undersigned officer to execute this document as of the date first written above.

 

SYNDAX PHARMACEUTICALS, INC.
By:  

/s/ Briggs Morrison

Name:   Briggs Morrison, M.D.
Title:   Chief Executive Officer